Survival rate (95% confidence interval) | ||||
1 year | 3 years | 5 years | p-value | |
Overall survivala | 95.2 (82.2 - 98.8) | 56.3 (36.0 - 72.4) | 42.6 (23.2 - 60.8) | |
Age (years) | ||||
<60 | 75.0 (12.8 - 96.1) | 75.0 (12.8 - 96.1) | 0.475 | |
60 - 70 | 82.2 (45.5 - 95.2) | 41.1 (10.0 - 70.9) | ||
70 - 80 | 94.1 (65.0 - 99.2) | 51.3 (20.3 - 75.7) | ||
>80 | 80.0 (20.4 - 96.9) | |||
ISUP grade groupb | ||||
1 | 50.0 (0.6 - 91.0) | 0.061 | ||
2 | 66.7 (5.4 - 9.5) | |||
3 | 85.7 (33.4 - 97.9) | 64.3 (15.2 - 90.2) | ||
4 | 76.2 (33.2 - 93.5) | 19.1 (0.9 - 55.9) | ||
5 | 90.9 (50.8 - 98.7) | 35.5 (8.6 - 64.5) | 11.8 (1.0 - 40.4) | |
PSA (initial, ng/mL) | ||||
≤100c | 80.8 (42.4 - 94.9) | 0.461 | ||
>100d | 88.9 (69.4 - 96.3) | |||
PSA (nadir, ng/mL) | ||||
<4 | 100 | 83.1 (47.2 - 95.5) | 83.1 (47.2 - 95.5) | 0.005 |
≥4 | 91.6 (70.2 - 97.8) | 29.2 (7.6 - 55.6) | 9.7 (0.6 - 34.8) | |
<4 in ≤12 mo | 100 | 83.1 (47.2 - 95.5) | 83.1 (47.2 - 95.5) | 0.002 |
<4 in >12 mo | 100 | 66.7 (5.4 - 94.5) | 0 | |
≥4 in >12 mo | 91.6 (70.2 - 97.8) | 29.2 (7.6 - 55.6) | 9.7 (0.6 - 34.8) | |
Time to PSA nadir | ||||
≤6 months | 100 | 43.7 (17.0 - 67.9) | 34.9 (11.3 - 60.2) | 0.263 |
7 - 12 months | 100 | 62.5 (14.2 - 89.3) | 62.5 (14.2 - 89.3) | |
>12 months | 100 | 83.3 (27.3 - 97.5) | 62.5 (14.2 - 89.3) | |
HN or paralysis | ||||
Present | 86.5 (55.8 - 96.5) | 16.5 (1.1 - 48.7) | 0.090 | |
Absent | 96.2 (75.7 - 99.5) | 47.5 (21.3 - 69.9) | ||
HT or diabetes | ||||
Present | 90.9 (50.8 - 98.7) | 35.4 (6.1 - 68.0) | 0.757 | |
Absent | 93.3 (75.7 - 98.3) |
| 38.0 (16.2 - 59.9) |